PET and Prognosis in Hodgkin Lymphoma: Prospective Analysis

Progression-free survival at 2 years was predicted by negative PET scan findings after the first 2 cycles of induction chemotherapy.

Retrospective studies have supported a role for [¹⁸F]fluoro-2-deoxy-d-glucose positron emission tomography (PET) imaging in predicting risk for progression or relapse in patients with Hodgkin lymphoma (HL; Journal Watch Oncology and Hematology Sep 18 2007). Small studies also suggest value for early PET imaging (after 2 to 4 cycles of chemotherapy) as a predictor of outcome following initial treatment. Italian and Danish investigators now report their findings on the prognostic value of early interim PET scanning, performed after 2 cycles of ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, dacarbazine) chemotherapy in patients with HL. The prognostic ability of PET findings was compared with that of the International Prognostic Score…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee